Breaking News, Collaborations & Alliances

AzurRx, Delpharm Enter Manufacturing Agreement

For the clinical drug product supply of MS1819 therapy for exocrine pancreatic insufficiency

By: Contract Pharma

Contract Pharma Staff

AzurRx BioPharma, a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, has entered into a manufacturing agreement with Delpharm, a contract development manufacturing organization (CDMO), for the clinical drug product supply of its MS1819 therapy for exocrine pancreatic insufficiency (EPI).   Delpharm will manufacture AzurRx’s MS1819 cGMP batch that will be used in the Phase 2b OPTION 2 Clinical Trial for the treatment of EPI in patients ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters